Ube Industries, Inc.

Daiichi Sankyo Company, Limited

Noriaki Iwase

Shigeyuki Kono

Tomio Kimura

Shigeru Ushiyama

Makoto Okudo

Masaaki Matoyama

Hidetoshi Sunamoto

Yusuke Shiraishi

Masahiro Kojima

Yasuhiro Aga

Satoshi Umezaki

Masayuki Tanaka

Masahiko Hagihara

Hiroshi Nishida

Eiji Okanari

Masaaki Ito

Sayaka Ogi

Kazuhiro Onuma

Hirofumi Matsunaga

Kenji Nishikawa

Takashi Matsushita

Tetsushi Katsube

Koji Ito

Katsunori Takata

Kenji Yoneda

Tomoko Kanda

Osamu Kikuchi

Hayato Nishiyama

Katsumasa Harada

Tsuyoshi Nakamura

Akio Matsushita

Takafumi Hirakawa

Hidenori Namiki

Katsuhiko Mizutare

Nobuhiko Shibakawa

Naoki Terasaka

Taku Nakamura

Takahiro Motoyama

Manabu Shigetomi

Ken Ikuno

Hiroyuki Setoguchi

Kiyoshi Yamamoto

Yukinori Kawai

Akiko Shima

Kazunari Tsuboike

Takayuki Nakanishi

The present invention provides a compound represented by general formula (I) or a pharmacologically acceptable salt thereof. [In the formula, the two Rs each independently represents a Calkyl group, or are bonded together to form a Calkylene group, A represents a Caryl group (which may be a substituted Caryl group), Z represents a hydrogen atom or a Calkyl group (which may be a substituted Caryl group), or A and Z may be bonded to each other, with the group represented by Z—N-A forming a bicyclic fused heteroaryl group, which may be substituted, and R, R, and Reach independently represents a linear or branched Calkyl group that may be substituted.]

Dihydropyrrolopyrazole derivative

Methods of producing a compound represented by formula (I) or a pharmacologically acceptable salt thereof include: wherein Lis an optionally substituted Calkylene group or the like, Lis a single bond or the like, Lis a single bond or the like, R, R, and Rare each independently an optionally substituted Calkyl group or the like, Ris a hydrogen atom or the like, and Ris a hydrogen atom or the like.

Substituted dihydropyrrolopyrazole compound

The present invention provides a compound represented by the general formula (Ia) or a pharmacologically acceptable salt thereof. In the general formula (Ia), two R moieties each independently represent a Calkyl group or the like; and R, Rand Reach independently represent an optionally substituted linear or branched Calkyl group. 

Substituted dihydropyrrolopyrazole derivative

A novel &#x3b1;-halogen-substituted thiophene compound or a pharmacologically acceptable salt thereof, which has a potent LPA receptor-antagonist activity and is useful as a medicament is provided. A compound represented by the general formula (I) wherein A represents, a phenyl ring, a thiophene ring, or an isothiazole ring; Ris the same or different, and represents a halogen atom, or a C-Calkyl group; Rrepresents a hydrogen atom, or a C-Calkyl group; p represents an integer of 0 to 5; V represents CRwherein Rrepresents a hydrogen atom, an amino group, a nitro group, or a C-Calkoxy group, or V represents a nitrogen atom; and X represents a halogen atom, or a salt thereof.

Halogen-substituted heterocyclic compound

Provided is a compound represented by formula (I) or a pharmacologically acceptable salt thereof: wherein Lis an optionally substituted Calkylene group or the like, Lis a single bond or the like, Lis a single bond or the like, R, R, and Rare each independently an optionally substituted Calkyl group or the like, Ris a hydrogen atom or the like, and Ris a hydrogen atom or the like.

The invention provides a novel &#x3b1;-halogen-substituted thiophene compound salt that has a potent LPA receptor antagonistic action and is useful as a medicament. The salt is represented by the general formula (I):  

Halogen-substituted heterocyclic compound salt

A novel &#x3b1;-halogen-substituted thiophene compound or a pharmacologically acceptable salt thereof, which has a potent LPA receptor-antagonist activity and is useful as a medicament is provided.

The present invention provides a substituted biaryl compound of general formula (I): 

Substituted biaryl compound

The present invention provides a salt of a substituted pyridine compound which has excellent CETP inhibition activity and is useful as a medicament. The present invention provides a salt of a compound represented by general formula (I): wherein Ris optionally substituted alkoxy or the like.

Acid addition salt of substituted pyridine compound

The present invention provides a substituted pyridine compound or a pharmacologically acceptable salt thereof which has excellent CETP inhibition activity and is useful as a medicament. The present invention provides a compound represented by a general formula (I), wherein Ris H, optionally substituted alkyl, OH, optionally substituted alkoxy, alkylsulfonyl, optionally substituted amino, carboxy, optionally substituted carbonyl, CN, halogeno, optionally substituted phenyl, optionally substituted aromatic heterocyclyl, optionally substituted saturated heterocyclyl, optionally substituted saturated heterocyclyloxy or optionally substituted saturated heterocyclylcarbonyl, etc., and the like.

Substituted pyridine compound

The present invention discloses a pyrrolopyridazinone compound represented by the formula (1):  useful, for example, as an anti-inflammatory agent or an inhibitor of respiratory tract contraction.

Pyrrolopyridazinone compound

Disclosed is a method for preparing 2-mercaptothiazole, which comprises adding a dithiocarbamate salt represented by the formula (1): ##STR1## wherein M is a cation, to a chloroacetaldehyde solution in the presence of an acid.

Method for preparing 2-mercaptothiazole

Growing community of inventors

Ube, Japan

Noriaki Iwase